The Prevalence of Metabolic Syndrome among Type 2 Diabetic Patients according to NCEP ATP III and IDF at Baba GurGur Diabetic Center, Kirkuk, Iraq

Abstract
Background: Metabolic syndrome (MetS) is a cluster of
metabolic abnormalities that strongly associated with the
development of cardiovascular disease (CVD) and type 2
diabetes mellitus T2DM. There are an increasing number of
metabolic syndrome (MetS) patients worldwide, and there is no
exception in Iraq. Regardless of which criteria are used for
diagnosis of metabolic syndrome, the first concern is early
detection of cardiovascular complication and early intervention.
Aim: The purpose of this study is to assess the prevalence of
clinical and biomarker component of metabolic syndrome using
NCEP ATP III (2005), IDF (2006) among Iraqi sample of
patients with type II diabetes.
Patients and methods: Four hundred-six, type 2 diabetic
patients attending Baba GurGur Diabetic Center in K1 Hospital/
Northern Oil Company –Kirkuk, from 1st April till 30th June,
were subjected randomly to this descriptive cross-sectional
study with mean age of 54.8740 ± 9.648. Clinical and
biochemical data were collected and the data was analyzed in
order to identify prevalence of MetS in these patients.
Results: The result showed that there was statistically
significant relation between sex and MetS in both Definitions
[NCEP ATP 111and IDF] with p value (0.000). The overall
prevalence of MetS among the studied sample was 51.2% and
48.9% in both definitions respectively. The frequency ofmetabolic Syndrome component was higher for Low HDL
Cholesterol and there was a highly statistically significant
relation between low HDL among female vs. male with p value
(0.000). High frequencies of MetS were between the age group
50-59 years. Regarding BMI, diabetic patients with BMI
(25-29.9) and (30-39.9) having highest frequency of Mets.
Conclusion: The prevalence of MetS and its components
using NCEP-ATPIII and IDF criteria amongst a sample of
T2DM Iraqi patients was high. Early diagnosis and proper
management is requested for metabolic syndrome to prevent
cardiovascular complication.